Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:38 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2041–2064 of 22,242 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: control 2 Clear all

Conditions: Diabetic Kidney Disease
Interventions: BMS-813160, Placebo matching with BMS-813160; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Not listed
Enrollment: 319 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 43
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more

Conditions: Allergic Rhinitis, Chronic Urticaria
Interventions: Levocetirizine 1.25 mg, Placebo; Drug · Other
Lead sponsor: UCB Pharma; Industry
Eligibility: 6 Months to 11 Months
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008
U.S. locations: 26
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Jonesboro, Arkansas + 23 more

Conditions: Rotator Cuff Tears, Full-thickness Rotator Cuff Tears
Interventions: nanofiber scaffold; Device
Lead sponsor: Atreon Orthopedics; Industry
Eligibility: 55 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 4
States / cities: Fishers, Indiana • Saint Clair Shores, Michigan • Cincinnati, Ohio + 1 more

Conditions: Pain, Hernia
Interventions: Ibuprofen, Opioid Medication, Placebo, Ibuprofen + Opioid medication; Drug
Lead sponsor: Mike O'Callaghan Military Hospital; Federal
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Nellis Air Force Base, Nevada

Conditions: Type2 Diabetes Mellitus
Interventions: Bexagliflozin tablets, 20 mg, Bexagliflozin tablets, placebo; Drug
Lead sponsor: Theracos; Industry
Eligibility: 20 Years and older
Enrollment: 351 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 26
States / cities: Birmingham, Alabama • Foley, Alabama • Little Rock, Arkansas + 21 more

Conditions: Asthma
Interventions: Heart rate variability biofeedback, Placebo; Behavioral
Lead sponsor: Fred Wamboldt, MD; Other
Eligibility: 18 Years to 75 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2018
U.S. locations: 2
States / cities: Denver, Colorado • Piscataway, New Jersey

Conditions: Hypogonadotropic Hypogonadism, Type 2 Diabetes
Interventions: testosterone, clomiphene, placebo; Drug
Lead sponsor: State University of New York at Buffalo; Other
Eligibility: 18 Years to 40 Years · Male only
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Diabetic Macular Edema
Interventions: RGX-314 Dose 1, RGX-314 Dose 2, Aflibercept (2.0 mg); Genetic · Biological
Lead sponsor: Sierra Eye Associates; Other
Eligibility: 25 Years to 89 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Reno, Nevada

Conditions: Congenital Ichthyosis
Interventions: PAT-001, 0.1%, PAT-001, 0.2%, Vehicle for PAT-001 0.1%, Vehicle for PAT-001 0.2%; Drug
Lead sponsor: Patagonia Pharmaceuticals, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: San Diego, California • New Haven, Connecticut • Chicago, Illinois + 2 more

Conditions: Hepatitis C, Chronic; AUD
Interventions: Brief alcohol counseling, Group and Individual Therapy Sessions; Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetes Mellitus, Type 2
Interventions: Qigong therapy, Progressive resistance training; Other
Lead sponsor: Bastyr University; Other
Eligibility: 18 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Kenmore, Washington

Conditions: ADHD
Interventions: tRNS; Device
Lead sponsor: Innosphere; Industry
Eligibility: 7 Years to 12 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 4
States / cities: Boston, Massachusetts • Rochester, Minnesota • Houston, Texas

Conditions: Preterm Pregnancy, Labor Induction
Interventions: Early Amniotomy, Late Amniotomy; Procedure
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older · Female only
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Smoking Cessation
Interventions: CP-526,555 (varenicline); Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 625 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2002
U.S. locations: 7
States / cities: Los Angeles, California • Farmington, Connecticut • Minneapolis, Minnesota + 4 more

Conditions: Healthy
Interventions: Endotoxin, Placebo; Biological · Other
Lead sponsor: Robert J Noveck, M.D.; Other
Eligibility: 18 Years to 40 Years
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Pain, Muscle, IUD
Interventions: Sweet Marjoram Essential Oil, Grapeseed Oil; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Green Bay, Wisconsin

Conditions: FSGS, Focal Segmental Glomerulosclerosis, Glomerulosclerosis
Interventions: Placebo, CCX140-B; Other · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 9
States / cities: Phoenix, Arizona • Torrance, California • Shreveport, Louisiana + 6 more

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: liraglutide, sitagliptin, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 407 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 58
States / cities: Phoenix, Arizona • Tucson, Arizona • Escondido, California + 46 more

Conditions: Recurrent Prostate Cancer
Interventions: MGE, Placebo, ADT; Drug · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older · Male only
Enrollment: 106 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 2
States / cities: Salisbury, North Carolina • Winston-Salem, North Carolina

Conditions: Acne Vulgaris
Interventions: Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel, DUAC® Gel, Placebo; Drug
Lead sponsor: Zydus Lifesciences Limited; Industry
Eligibility: 12 Years to 40 Years
Enrollment: 850 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 12
States / cities: Dinuba, California • Santa Ana, California • Boynton Beach, Florida + 9 more

Conditions: Overweight, Obesity
Interventions: 500 mL/day of a beverage providing approximately 625 mg catechins, Control beverage matched for energy and caffeine content; Dietary Supplement · Other
Lead sponsor: Provident Clinical Research; Other
Eligibility: 21 Years to 65 Years
Enrollment: 132 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2007
U.S. locations: 2
States / cities: St. Petersburg, Florida • Bloomington, Indiana

Conditions: Graft Rejection
Interventions: Placebo, C1 Esterase Inhibitor (Human); Biological
Lead sponsor: Shire; Industry
Eligibility: 18 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 4
States / cities: Los Angeles, California • Baltimore, Maryland • Minneapolis, Minnesota + 1 more

Conditions: Postoperative Pain
Interventions: Pregabalin, Acetaminophen, Placebo 1, Placebo 2; Drug · Other
Lead sponsor: Nevakar, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 2
States / cities: Pasadena, California • Bellaire, Texas

Conditions: Type I Hypersensitivity
Interventions: Grass MATA MPL, Placebo; Biological
Lead sponsor: Allergy Therapeutics; Industry
Eligibility: 18 Years to 59 Years
Enrollment: 1,028 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 65
States / cities: Colorado Springs, Colorado • Denver, Colorado • Englewood, Colorado + 58 more

Search by objective public record fields.

Study to Evaluate the Effects of BMS-813160 on Protein Loss in the Urine of Subjects With Type 2 Diabetes and Diabetic Kidney Disease

Safety Study of Levocetirizine Dihydrochloride Oral Liquid Formulation in Children Aged 6 Months to 11 Months

Rotator Cuff Healing Using a Nanofiber Scaffold in Patients Greater Than 55 Years

Ibuprofen to Decrease Opioid Use and Post-operative Pain Following Unilateral Inguinal Herniorrhaphy

Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects

Heart Rate Variability Biofeedback: It's Role in Asthma Therapeutics

Hypogonadism in Young Men With Type 2 Diabetes

Phase 2 Trial of RGX-314 in Adults With Center Involved - Diabetic Macular Edema (CI - DME)

A Safety and Tolerability Study of Topical PAT-001 in Congenital Ichthyosis

Hepatitis C Alcohol Reduction Treatment

Effects of Qigong on Type 2 Diabetic Patients

tRNS Treatment for ADHD Symptoms

Preterm Induction of Labor Timing of Amniotomy: A Randomized Controlled Trial

A Seven-Week Dose-Ranging Study of CP-526,555 Compared With Placebo and Zyban for Smoking Cessation

Dose-Related Inflammatory Effects of Intravenous Endotoxin in Humans

Essential Oils Following IUD Insertion

A Study of CCX140-B in Subjects With FSGS

Efficacy and Safety of Switching From Sitagliptin to Liraglutide in Subjects With Type 2 Diabetes Not Achieving Adequate Glycaemic Control on Sitagliptin and Metformin

Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy

To Compare the Efficacy and Safety of Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel of CHL Versus DUAC® Gel

Efficacy of a Tea Catechin Sports Drink for Enhancing Exercise-Induced Fat Loss

A Pilot Study to Evaluate the Use of C1 Esterase Inhibitor (Human) in Patients With Acute Antibody-Mediated Rejection

A Phase 2 Study to Evaluate Pregabalin and Acetaminophen Compared to Acetaminophen and Placebo in Subjects Undergoing Bunionectomy

Efficacy and Safety/Tolerability of Grass MATA MPL